摘要
目的 探讨体外化疗药敏试验系统 (ATP TCA系统 )联合流式细胞仪 (FCM )在肝癌化疗中的应用及其结果之间的关系。方法 取 2 4例肝癌切除、活检或穿刺组织行体外药敏试验和流式细胞仪P170 检测 ,并分析二者间的关系。结果 ATP TCA的可评估率为 91 6 7% ;10种化疗药物的敏感率分别为 :氟尿嘧啶 5 0 0 %、诺消灵 5 0 0 %、顺铂 14 2 6 %、足叶乙甙 19 0 5 %、草酸铂 19 0 5 %、丝裂霉素 2 3 81%、表阿霉素 2 8 5 7%、开普拓 45 46 %、健择 47 6 2 %、泰素 6 3 6 4% ;P170 检测阳性率为 5 7 14% ;丝裂霉素、表阿霉素的敏感率在P170 阴性表达时高 ,开普拓、健择、泰素的敏感率高且在P170 阳性表达和阴性表达时无显著差异。结论 ATP TCA法联合FCM可较好用于肝癌化疗药物的筛选 ;丝裂霉素、表阿霉素可用于P170 阴性表达的病人 ,开普拓、健择、泰素可用于P170 阳性表达的病人。
Objective To study the application of in vitro ATP tumor chemosensitivity assay (ATP-TCA) and flow cytometry (FCM) in chemotherapy of primary liver cancer. Methods The specimens of primary liver cancer from 24 patients were tested by ATP-TCA and FCM. Results Evaluable test results were achieved in 22 of the 24 patients and the evaluability was 91.6%. The sensitive rates of 5-Fluoruracil (5-Fu), mitoxantron (MIT), cisplatin (CDDP), etoposid (Vp-16), oxaliplatin (OXA), mitomycin C (MMC), epirubicin (EPI), irinotecan (CPT), gemcitabine (GEM) and paclitaxl (TAX) were 5.00%, 5.00%, 14.29%, 19.05%, 19.05%, 23.81%, 28.57%, 45.46%, 47.62% and 63.60%, respectively. The positive rate of P 170 was 57.14%. The sensitive rates of MMC and EPI were higher in P 170 negative patients than in P 170 positive ones. The sensitive rates of CPT, GEM and TAX were high and there was no difference in sensitivity between different P 170 expression patterns. Conclusions ATP-CTA and FCM can be applied in screening of chemotherapeutic agents for primary liver cancer. MMC and EPI can be used in patients with negative P 170 expression and CPT, GEM and TAX in those with positive P 170 expression.
出处
《中华肝胆外科杂志》
CAS
CSCD
2002年第12期728-731,共4页
Chinese Journal of Hepatobiliary Surgery
基金
广东省社会发展重大科技项目 (NO :2KM 0 45 0S)
关键词
体外药敏试验
ATP-TCA
流式细胞仪
肝癌
化疗
多耐药基因
Carcinoma, hepatocellular
In vitro chemosensitivity assay
Flow cytometry
Primary liver cancer
Multidrug resistance
P 170
